Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted1 study · 80 participantsVery low
Findings
What do systematic reviews say?
12 questions · 12 findings · 1 reviews
No studies found 2 · 16.7%GRADE not reported 0 · 0%Very low 8 · 66.7%Low 2 · 16.7%Moderate 0 · 0%High 0 · 0%
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.54 [0.07, 36.11]1 study · 60 participantsLow
Minoxidil vs placebo
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted4 studies · 304 participantsVery low
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted1 study · 80 participantsVery low
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo
Incidence of serious adverse events · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 0.33 [0.01, 7.94]1 study · 78 participantsVery low
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted4 studies · 154 participantsVery low
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.47 [0.6, 3.6]3 studies · 1224 participantsLow
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted2 studies · 79 participantsVery low
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted4 studies · 543 participantsVery low
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
- no estimate extracted1 study · 30 participantsVery low
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found